Bio Assays - Commentary – First Supplement to USP 35-NF 30
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
Amongst others, the USP published the received comments and responses to General Chapter/Section: <1032> Design and Development of Biological Assays in the Commentary – First Supplement to USP 35-NF 30.
The USP received 13 comments to different parts of this chapter. Comments to the following topics are included:
- Necessary Harmonization with compendial references e.g. European Pharmacopoiea
- Helpful case study examples that illustrate the application
- The need that the assay acheive a specific observable response
- Assessment of similarity using the entire concentration-response curve, including the asymptotes.
- Potency assay for assessment of stability
- Need of documenting the source of assay's cell line
The complete comments can be found at Commentary – First Supplement to USP 35-NF 30.
In this respect you may also want to pay attention to ECA's New Education Course on "Bioassays, and Bioanalytics" from 27-28 March 2012 in Copenhagen, Denmark.
Author:
Axel H. Schroeder
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
23.04.2026Revised Chapter 2.8.25 HPTLC of Herbal Products” Published in Ph. Eur. 13.1
22.04.2026USP plans new General Chapter on Supercritical Fluid Chromatography (SFC)
08.04.2026FDA Warning Letter: Batch Release Without Appropriate Laboratory Evidence
01.04.2026FDA Warning Letter - From Garbage Bags with Analytical Records to Pre-signed and Backdated Data
31.03.2026Questions and Answers on System Suitability Tests (SST) - Part 3
31.03.2026Statistical Process Control (SPC) - Survey Result Report now Available